Background: Airway inflammation is associated with an increased expression and release of inflammatory reactants that regulate processes of cell migration, activation and degranulation. The purpose of this study was to quantify bronchial lavage (BAL) fluid and serum levels of chemokine (IL-8), secretory leukocyte protease inhibitor (SLPI), soluble intracellular adhesion molecules-1 (sICAM-1) and sCD14, as surrogate markers of inflammatory and immune response in asthma and chronic obstructive pulmonary disease (COPD) patients with similar disease duration time. Methods: Biomarkers in serum and BAL fluid from asthma (n ¼ 13) and COPD (n ¼ 25) patients were measured using commercially available ELISA kits. Results: We found that in asthma and COPD groups the concentrations of IL-8 and SLPI are significantly higher in BAL fluid than in serum, while levels of sICAM-1 and sCD14 in BAL fluid are significantly lower than in serum. Of these 4 measured biomarkers, only the BAL IL-8 was higher in COPD patients when compared to asthma (Po0.05). In both groups, BAL IL-8 correlated with SLPI (r ¼ 0.577, Po0.01 and r ¼ 0.589, Po0.05, respectively). In patients with COPD the BAL sICAM-1 correlated with sCD14 (r ¼ 0.576, Po0.01), while in asthma patients BAL sICAM-1 correlated with FEV 1 /FVC (r ¼ 0.418, Po0.01). Moreover, in asthma patients the serum SLPI correlated with sCD14 (r ¼ 0.688, Po0.01) and serum sICAM-1 negatively correlated with FEV 1 /FVC (r ¼ À0.582, Po0.05). Conclusion: Our findings point to the importance of selecting a correct biological fluid when analyzing specific biomarkers, and also show that of 4 measured biomarkers, only the BAL IL-8 was higher in COPD patients when compared to asthma.
Introduction
Airway inflammation is a cardinal pathophysiological feature in patients with asthma and chronic obstructive pulmonary disease (COPD). Both diseases are associated with an increased expression and release of inflammatory reactants, including cytokines, chemokines, proteases and their inhibitors, and adhesion molecules that regulate processes of cell migration, activation and degranulation. 1, 2 Recent studies show similar cellular responses in asthma and COPD, with raised levels of neutrophils in more severe forms of asthma 3, 4 and raised counts and activation of eosinophils in COPD. [5] [6] [7] Monocytes/macrophages are a significant component of the inflammatory infiltrate in COPD 8 and several studies show that monocytes/macrophages are in an activated state in asthma and orchestrate immune reactions. 9, 10 For instance, levels of CD14, a marker of monocyte/macrophage activation, 11 have been shown to be increased in asthma patients during acute asthma attacks. [12] [13] [14] IL-8 occurs at high levels in COPD and is a selective attractant of neutrophils and IL-8 levels in induced sputum are correlated with the extent of neutrophilic inflammation and with disease severity (% predicted FEV 1 ). 15, 16 IL-8 has also been suggested to play a role in asthma, where it is reported to be involved in lymphocyte, eosinophil and basophil activation and migration to the inflammatory site.
Adhesion molecules are important in the recruitment and migration of leukocytes from circulation to the inflammatory sites. Elevated cell surface expression of intercellular adhesion molecule-1 (ICAM-1) has been demonstrated in asthmatic airways 17, 18 and increased levels of soluble ICAM-1 (sICAM-1) has been found in asthmatic sputum. 19 Whether ICAM-1 is up-regulated to the same extent in COPD remains uncertain, as the studies published so far have yielded conflicting results. [18] [19] [20] Proteases and their inhibitors are also implicated in the pathophysiology and airway pathology of COPD as well as asthma. 21 Secretory leukocyte protease inhibitor (SLPI), also known as antileukoprotease, is a naturally occurring serine proteinase inhibitor produced by mucosal epithelial cells, serous cells, and bronchiolar goblet cells in human airways. 22, 23 Historically, this inhibitor was first purified from lung secretions of patients with COPD and cystic fibrosis. However, emerging evidence suggests that SLPI is also important in the pathophysiology of asthma because it exhibits broad-spectrum inhibitory activity against mast cell and leukocyte serine proteases implicated in asthma pathology. [24] [25] [26] Thus, inflammation in the respiratory tract involves epithelial cells, resident macrophages, eosinophils, and neutrophils, and provides many cell-released markers that can be used to follow pathophysiological changes related to the disease. The majority of protein expression changes are closely associated with many aspects of the pathophysiology of disease, including inflammation, airway remodelling, tissue damage and repair, mucus production, and plasma infiltration. 27 However, an understanding of the relationship between the complex array of cells and mediators involved in asthma and COPD is not yet fully dissected which makes difficult to find a specific and sensitive panel of biomarkers that can reflect intensity of these pathological processes and can help to predict the individual outcome. It is well known that the validation of specific biomarkers requires the choice of appropriate biological medium for analysis, therefore we aimed to measure and to compare serum and BAL fluid concentrations of SLPI, sICAM-1, IL-8 and sCD14 -as potential inflammatory markers in asthma and COPD patients.
Materials and methods

Subjects
The studied group consisted of COPD (n ¼ 25) and asthma (n ¼ 13) hospital outpatients, age 435 years from the Department of Pulmonology and Immunology, Kaunas Medical University Hospital, Lithuania. The COPD diagnosis was based on the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. 28 Patients included in the study had a forced expiratory volume in one second (FEV 1 ) of o80% of predicted and a FEV 1 /FVC (forced vital capacity) ratio ofo70% of predicted, classified as moderate (n ¼ 13) to severe (n ¼ 12) COPD (GOLD stages II-III). In to the study there were included COPD patients with a smoking history (current or ex-smoker) of X10 pack-years or never-smokers (n ¼ 4) who have exposure to occupational dust and chemicals.
Adult asthmatics with a history of asthma of 6 months or more were diagnosed according to the standards of the Global Initiative for Asthma. 29 All patients were steroidnaïve or without inhaled and systemic steroids for at least 1 month before the study. None of the subjects showed signs of acute respiratory infection at least 1 month before the investigation.
The exclusion criteria were a1-antitrypsin deficiency, dyspnea of other origin (including cardiovascular disorders, pneumonia, interstitial lung disease, pleural disease, upper airways obstruction, neuromuscular disease and anaemia) and bronchial carcinoma. Number of smoking pack-years was calculated as the product of tobacco use (in years) and the average number of cigarettes smoked per day/20 (year's Â cig. per day/20). The study was approved at the Regional Bioethics Committee (protocol no. 48/2004) and written informed consent was received from all participants.
Lung function testing
Pulmonary function was tested using a pneumotachometric spirometer ''Custo vitM'' (Custo Med, Germany) with subjects in the sitting position, and the highest value of FEV 1 and FVC from at least two technically satisfactory maneuvers differing by less than 5% was recorded. Normal values were characterized according to Quanjer. 30 Subjects had to avoid the use of long-acting b 2 -agonists for at least 48 h and short-acting b 2 -agonists for at least 8 h prior to the test.
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Bronchoscopy and bronchoalveolar lavage processing
Bronchoscopy was performed after the blood sampling and lung function testing. Subjects were not allowed to drink or eat at least 4 h prior the bronchoscopy. Smoking was not allowed at least 10 h before the procedure. To perform BAL, the local upper airways were anaesthetized with 5 ml of 2% Lidocaine (Grindex, Latvia). All bronchoscopic examinations were performed in the morning. The bronchoscope (Olympus, USA) was wedged into the segmental bronchus of the middle lobe and 5 boluses of 20 ml sterile saline solution at 37 1C was infused. Fluid was gently aspirated immediately after the infusion had been completed and was collected into a sterile container with a negative pressure of À40 to 50 mmHg. The fluid was immediately filtered using 48 mm nylon gauze (Millipore, North Ryde, NSW, Australia) and centrifuged at À4 1C for 10 min. Supernatants were removed and frozen in Eppendorf tubes at À70 1C for further investigation. All patients underwent bronchoscopic procedures without any significant complication.
Serum samples
Blood samples were drawn in serum tubes, clotted at room temperature for 30-60 min and centrifuged for 10 min at 3900 rpm. Serum samples were immediately frozen at À70 1C for further assay.
Analysis of serum and bronchial lavage (BAL) fluid
The serum and BAL fluid concentrations of IL-8, sICAM-1, sCD14 and SLPI were determined using commercially available quantitative enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems Minneapolis, USA) according to the manufacturer's instructions. Assays were performed in duplicate and the optical density at 450 nm, with a background correction at 570 nm, was determined using a microplate reader (Labsystems iEMS Reader MF). The readings for each standard and sample were averaged and the average of the zero standard was subtracted. The detection limits of the IL-8, sICAM-1, sCD14-1 and SLPI kits were 31.2, 15.6, 125 and 62.5 pg/ml, respectively.
Analysis of total protein in BAL fluid
The protein concentration in the lavage fluids was measured by Bradford protein assay according to manufacturer's recommendations (Sigma, USA). 31 
Statistical analysis
Statistical analysis was performed using the SPSS software (version 12.0.1 for Windows, SPSS Inc., Chicago, IL, USA). Normal distribution of the variables was tested using the Kolmogorov-Smirnov test and since log-transformation of non-normally distributed variables did not improve the normal distribution, non-parametric tests were used. The Kruskal-Wallis test was used for comparisons between more than two groups and if significance was reached, the Mann-Whitney U test, with correction for multiple comparisons (Bonferroni), was used for group-wise comparisons. Correlations were investigated using the Spearman rank order correlation test. Data is presented as mean and range. Table 1 gives the demographic data, disease duration, lung function and smoking habits of the investigated asthma and COPD patients. The asthma patients were younger than the COPD group (P ¼ 0.026), had more females than males (69.2% vs. 8.7%, respectively) and included significantly fewer smokers. Out of 25 COPD patients, 4 were never smokers and 11 ex-smokers. As expected, COPD patients had lower FEV 1 (FEV 1 % of predicted 58.3 vs. 84.1, Po0.001) compared to asthma patients. No significant difference was found between asthma and COPD patients in disease duration time (8.672.5 vs. 7.871.3 years), serum AAT levels (1.4775.6 vs. 1.3875.4 mg/ml) and the concentration of total BAL fluid proteins.
Results
Patient characteristics
Concentrations of IL-8, SLPI, sICAM-1 and sCD14 in BAL and serum
The concentration of BAL IL-8 was significantly higher in the group with COPD than in the group with asthma (mean7SE: 0.10470.03 vs. 0.0370.01 ng/ml, P ¼ 0.04). No significant difference was observed between the two groups in serum IL-8 concentrations, although the mean levels were higher in COPD than in the asthma patients (mean7SE: 0.0970.07 vs. 0.01670.01 ng/ml). In both groups IL-8 concentrations were significantly higher in BAL fluid than in serum (COPD P ¼ 0.011 and asthma P ¼ 0.034).
As shown in Table 2 , we found no significant difference in BAL and serum SLPI, sICAM-1 and sCD14 concentrations Relationship between studied biomarkers in the group with asthma and COPD 
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As shown in
Discussion
Previously it has been demonstrated that IL-8 levels are increased in COPD patients, 15, 32 and that increased levels of IL-8 in sputum samples correlate with the airway bacterial load and proteinase released from activated neutrophils. 33 
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**Correlation is significant at the 0.01 level. *Correlation is significant at the 0.05 level.
-Non-significant.
Recently, Schulz and collaborators 34 have shown that in subjects with COPD the constitutive and stimulated IL-8 release is significantly higher compared to 'healthy' smokers and control subjects. Consistent with this, we also found higher concentrations of BAL fluid IL-8 in the patients with COPD than in those with asthma. It is important to note that our patient groups differ significantly in age, gender, and smoking habits; i.e. the asthma group includes predominantly never-smoking females while the COPD group is primarily smoking males. Thus, it is possible that the higher IL-8 levels in COPD patients are related to the above differences between the patient groups. It has been demonstrated that cigarette smoke induces the release of IL-8 from cultured human bronchial epithelial cells, 35 and BAL specimens from non-asthmatic smokers have greater concentrations of neutrophils, macrophages, and a number of cytokines, including IL-1b, IL-6, IL-8, and monocyte chemoattractant protein-1 than non-smokers. 36 So far, the differences and similarities in the pathological processes of COPD patients with and without a smoking history are not known. It is important to point out that 4 out of 25 COPD patients included in our study were never smokers and 11 ex-smokers. However, we found no association between BAL fluid or serum IL-8 levels and smoking history in the COPD group, suggesting that the mechanism for IL-8 release may depend on several factors, and not just simply on smoking alone. Furthermore, the BAL IL-8 level did not correlate with age and gender. The molecular mechanisms that trigger, maintain, and regulate the expression and release of IL- 8 have not yet been fully elucidated. For instance, bacterial endotoxin and tumor necrosis factor-alpha (TNF-a) are known to increase IL-8 production by epithelial cells. 37 It has been proposed that neutrophil elastase may also stimulate epithelial cells to produce more IL-8. 38 Neutrophil elastase has also been shown to increase SLPI transcription in primary human airway epithelial cells, 24, 26 and we found a direct correlation between BAL fluid IL-8 and SLPI concentrations in both COPD and asthma groups. However, SLPI, like IL-8, may also be up-regulated by bacterial endotoxins and cytokines such as IL-1 and TNFi. 39, 40 Inflammation in COPD and asthma extends beyond the airways, 41, 42 therefore the biomarkers reflecting systemic rather than local inflammation in the lungs may be of greater value in diagnosis. In support of this, the results of Little and collaborators 43 show that high levels of plasma intercellular adhesion molecule-1 (sICAM-1, CD54) and IL-8 in BAL fluid correlate with the development and severity of chronic lung disease. Increased levels of sICAM-1 in plasma and BAL from patients with COPD have been reported. [44] [45] [46] Serum concentrations of sICAM-1 were also found to be increased in acute asthma. 47 We found no significant difference in serum and BAL fluid sICAM-1 concentrations between the COPD and asthma groups. However, it is important to note that in patients with asthma the FEV 1 / FVC ratio showed direct correlation with BAL sICAM-1 but inverse correlation with serum sICAM-1. This finding is difficult to interpret, but it has been shown that in untreated asthmatics, ICAM-1 is over-expressed in bronchial epithelial cells. 18 The asthma patients included in our study were untreated for at least 1 month prior to sample collection and were in stable condition. This may explain why sICAM-1 was found to be correlated to lung function in asthma patients. In the COPD group, BAL fluid sICAM-1 correlated with soluble sCD14, an acute phase protein, mainly released from activated monocytes/macrophages and hepatocytes.
48 CD14-dependant mechanisms of inflammation have been discussed in acute respiratory distress syndrome, 49 sarcoidosis 50 and asthma. 51 The soluble form of CD14 is generated by proteolytic shedding of the membraneassociated form (mCD14) during cellular activation and can be detected proportionately in the BAL fluid. 52 We found significantly higher levels of sCD14 as well as sICAM-1 in serum compared to BAL.
In general, many markers of inflammation in BAL fluid may have a stronger signal than the same markers in blood and vice versa, therefore the information gained from such assays might be difficult to interpret. For instance, in the present study we have found that in asthma and COPD groups the concentrations of IL-8 and SLPI are significantly higher in BAL fluid than in serum while levels of sICAM-1 and sCD14 in BAL fluid are significantly lower than in serum. It is well known that the major sites of SLPI synthesis are Clara and goblet cells of the surface epithelium, 53, 54 and the serous cells of the sub mucosal glands. [55] [56] [57] Therefore, it is reasonable to believe that analysis of serum SLPI may only partially reflect the ongoing pathological process in the airways, and therefore too insensitive to monitor the actual state of disease. The relevance of circulating IL-8, sICAM-1 and sCD14 and their relation to locally production in COPD and asthma remain much less clear. Thus, the applicability of these biomarkers in respiratory diseases will much depend on the selection of a correct biological fluid when analyzing. Another important point, beside the compartment, is the biological reasoning to measure the specific biomarker. In order to avoid spurious association, the selected biomarker must fit to the current knowledge of the biochemical basis of the disorder.
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